US Stock MarketDetailed Quotes
NRXS Neuraxis
- 2.430
- +0.030+1.25%
Close Dec 27 16:00 ET
16.96MMarket Cap-2.01P/E (TTM)
2.800High2.340Low68.24KVolume2.460Open2.400Pre Close169.17KTurnover2.18%Turnover RatioLossP/E (Static)6.98MShares3.89052wk High-9.46P/B7.62MFloat Cap2.00052wk Low--Dividend TTM3.13MShs Float6.930Historical High--Div YieldTTM19.17%Amplitude1.800Historical Low2.479Avg Price1Lot Size
Neuraxis Stock Forum
Sign in to post a comment
NOTE: I don’t have time to include those in my watchlist which didnt run. Just go back to it because those stocks will go usually after days or a week.
Sorry I am sleepy cant finish the list.
$Rigetti Computing (RGTI.US)$ PR today 12/10: Quantum Machines And Rigetti Computing Announces The Application Of AI To Automate The Calibration Of A Quantum Computer. Up after hours. SI 13.89%, 0 shares LTB✅
$SEALSQ Corp (LAES.US)$ PR 12/10: Partnership with IC’ALPS to ...
Sorry I am sleepy cant finish the list.
$Rigetti Computing (RGTI.US)$ PR today 12/10: Quantum Machines And Rigetti Computing Announces The Application Of AI To Automate The Calibration Of A Quantum Computer. Up after hours. SI 13.89%, 0 shares LTB✅
$SEALSQ Corp (LAES.US)$ PR 12/10: Partnership with IC’ALPS to ...
68
11
6
$Neuraxis (NRXS.US)$
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
Tuesday, 10th December at 9:00 am
RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without needing electronics or software.
NeurAxis Inc. will begin the process of commercially marketing RED and expects initial revenues in 1Q25 as there is a Category I CPT code assigned to t...
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
Tuesday, 10th December at 9:00 am
RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without needing electronics or software.
NeurAxis Inc. will begin the process of commercially marketing RED and expects initial revenues in 1Q25 as there is a Category I CPT code assigned to t...
$Neuraxis (NRXS.US)$ NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market
3 MINUTES AGO, 9:00 AM EST
VIA GLOBENEWSWIRE
3 MINUTES AGO, 9:00 AM EST
VIA GLOBENEWSWIRE
1
$Lion Group (LGHL.US)$ $Neuraxis (NRXS.US)$ $Pacific Mercantile Bancorp (PNBK.US)$ $Powell Max (PMAX.US)$ $Inspire Veterinary Partners (IVP.US)$ $Lobo EV Technologies (LOBO.US)$ $DatChat (DATS.US)$ $Erayak Power Solution Group (RAYA.US)$ $Silexion Therapeutics (SLXN.US)$ $Venus Concept (VERO.US)$ $Highway Holdings (HIHO.US)$ $Genprex (GNPX.US)$ $Digital Brands Group (DBGI.US)$
📊⚡️📊
📊⚡️📊
4
2
$Neuraxis (NRXS.US)$ Neuraxis Announces New Submission to the FDA for the Expansion of Its Ib-Stim Label; Provides Compliance With NYSE Guidelines on Audit Disclosure
$Neuraxis (NRXS.US)$ NeurAxis Announces Publication Of Medical Policy Coverage For Percutaneous Electrical Nerve Field Stimulation With A Blue Cross Blue Shield License In FL
1
$Neuraxis (NRXS.US)$ NeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida Globe Newswire 16-May-2024 9:00 AM CARMEL, Ind., May 16, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimu...
Timothy Henrichs' appointment could be a game-changer for NeurAxis' strategic commercialization activities. His arrival comes at a crucial growth phase, potentially impacting the company's financial performance and stock value.
The secured funding is essential to accelerate the company's sales and marketing strategies. Additionally, increasing the policy coverage of IB-Stim(TM) and achieving clearance for RED serves as an opportunity to generate meaningful revenues from 2024 onwards.
NeurAxis CMO, Dr. Adrian Miranda, emphasized the economic impact of chronic constipation in the U.S. and the necessity for a screening tool like RED. CEO Brian Carrico sees the University of Michigan agreement as a chance to broaden NeurAxis' adult GI scope.
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
AW138 : thank you sir, always appreciate your posts
DaTrader AW138 : I second that
WILLEE9ice : tons of thanks master, you have has done the jobs
Jenna Ragan : Thank you kindly
Tottigol10 : I can't understand unfortunately..any recommendations on where i can start to study and get more into it?
View more comments...